{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:21:44Z","timestamp":1787235704946,"version":"build-2736575974"},"reference-count":28,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"unspecified","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,5,9]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Inflammatory bowel diseases (IBDs) and multiple sclerosis (MS) are inflammatory diseases resulting from an interplay of genetic and environmental factors. This study aims to describe the prevalence of patients diagnosed with both conditions among those receiving hospital care in England, as well as the characteristics and healthcare resource use (HCRU) of such patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This study is a retrospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study was conducted through secondary use of the English Hospital Episode Statistics (HES) Database. HES records care delivered by hospitals in England and associated diagnoses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients who had a diagnosis code for either IBD or MS recorded in HES between January 2014 and May 2020 were included. Patients were classified as having each diagnosis individually or as having both diagnoses, in which case they were further categorised based on temporal occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was the prevalence of patients with a recorded diagnosis of either IBD, MS or both during the study period. Secondary outcome measures included patient demographic and clinical characteristics, as well as HCRU in the 6 months before and after the diagnosis of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From an overall cohort of 352 698 patients, 1016 (0.3%) had both diagnoses. Among those with both, 29.8% (303) had a record of IBD first, 40.5% (411) had MS diagnosed first and 29.7% (302) had the first record of both diagnoses in the same episode. From the overall cohort, 80.9% (285 439) of patients had a single diagnosis of IBD, and 18.8% (66 243) of patients had a single diagnosis of MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The population with a dual diagnosis of IBD and MS is larger than previously reported and shows evidence of frequent interactions with secondary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-088808","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T05:30:22Z","timestamp":1750224622000},"page":"e088808","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical profile of patients with comorbid IBD and MS, and associated service impact in England\u2019s secondary care setting: a retrospective cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1606-6373","authenticated-orcid":false,"given":"Baptiste","family":"Coxam","sequence":"first","affiliation":[{"name":"Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Kew","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve","family":"Fraser","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Levick","sequence":"additional","affiliation":[{"name":"Harvey Walsh Limited, Runcorn, UK"},{"name":"OPEN Health Group, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Rolfe","sequence":"additional","affiliation":[{"name":"Harvey Walsh Limited, Runcorn, UK"},{"name":"OPEN Health Group, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey","family":"Ellison","sequence":"additional","affiliation":[{"name":"Harvey Walsh Limited, Runcorn, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin G","family":"Pollock","sequence":"additional","affiliation":[{"name":"Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"2025121513015471000_15.6.e088808.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-021-01716-6","article-title":"The incidence and prevalence of inflammatory bowel disease in UK primary care: a retrospective cohort study of the IQVIA Medical Research Database","volume":"21","author":"Freeman","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2025121513015471000_15.6.e088808.2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025121513015471000_15.6.e088808.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.03.003"},{"key":"2025121513015471000_15.6.e088808.4","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000622"},{"key":"2025121513015471000_15.6.e088808.5","unstructured":"Public Health England . Multiple Sclerosis: Prevalence, Incidence and Smoking Status - Data Briefing, 2020. Available: https:\/\/www.gov.uk\/government\/publications\/multiple-sclerosis-prevalence-incidence-and-smoking-status\/multiple-sclerosis-prevalence-incidence-and-smoking-status-data-briefing#references"},{"key":"2025121513015471000_15.6.e088808.6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2013.09.011","article-title":"New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease","volume":"13","author":"Lin","year":"2014","journal-title":"Autoimmun Rev"},{"key":"2025121513015471000_15.6.e088808.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602273140921"},{"key":"2025121513015471000_15.6.e088808.8","doi-asserted-by":"publisher","DOI":"10.4065\/75.8.802"},{"key":"2025121513015471000_15.6.e088808.9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acn3.51495","article-title":"Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"2025121513015471000_15.6.e088808.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.022"},{"key":"2025121513015471000_15.6.e088808.11","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.23011"},{"key":"2025121513015471000_15.6.e088808.12","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1038\/s41467-021-25768-0","article-title":"Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases","volume":"12","author":"Yang","year":"2021","journal-title":"Nat Commun"},{"key":"2025121513015471000_15.6.e088808.13","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211035542","article-title":"Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders","volume":"14","author":"Brummer","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2025121513015471000_15.6.e088808.14","unstructured":"NHS Digital . NHS digital. Hospital Episode Statistics (HES), Available: https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics"},{"key":"2025121513015471000_15.6.e088808.15","unstructured":"NHS England . Hospital Admitted Patient Care Activity 2020-21, 2021. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/hospital-admitted-patient-care-activity\/2020-21"},{"key":"2025121513015471000_15.6.e088808.16","unstructured":"NHS England . The HES Processing Cycle and Data Quality Checks, 2021. Available: https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\/hes-processing-cycle-and-data-quality-checks"},{"key":"2025121513015471000_15.6.e088808.17","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0326-3"},{"key":"2025121513015471000_15.6.e088808.18","unstructured":"World Health Organisation (WHO) . The ICD-10 Classification of Mental and Behavioural Disorders. 2019."},{"key":"2025121513015471000_15.6.e088808.19","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00851","article-title":"Comorbidity in Multiple Sclerosis","volume":"11","author":"Magyari","year":"2020","journal-title":"Front Neurol"},{"key":"2025121513015471000_15.6.e088808.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194623","article-title":"Emerging Comorbidities in Inflammatory Bowel Disease: Eating Disorders, Alcohol and Narcotics Misuse","volume":"10","author":"Ku\u017anicki","year":"2021","journal-title":"J Clin Med"},{"key":"2025121513015471000_15.6.e088808.21","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.17360.1","article-title":"A comprehensive high cost drugs dataset from the NHS in England - An OpenSAFELY-TPP Short Data Report","volume":"6","author":"Rowan","year":"2021","journal-title":"Wellcome Open Res"},{"key":"2025121513015471000_15.6.e088808.22","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-024-01776-w","article-title":"Inflammatory bowel disease is associated with an increase in the incidence of multiple sclerosis: a retrospective cohort study of 24,934 patients","volume":"29","author":"Yaqubi","year":"2024","journal-title":"Eur J Med Res"},{"key":"2025121513015471000_15.6.e088808.23","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12433"},{"key":"2025121513015471000_15.6.e088808.24","unstructured":"Office for National Statistics . Population of England and Wales, Available: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity\/national-and-regional-populations\/population-of-england-and-wales\/latest"},{"key":"2025121513015471000_15.6.e088808.25","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519887328"},{"key":"2025121513015471000_15.6.e088808.26","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819827692","article-title":"Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010","volume":"12","author":"Aniwan","year":"2019","journal-title":"Therap Adv Gastroenterol"},{"key":"2025121513015471000_15.6.e088808.27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063253","article-title":"The Inflammatory Conspiracy in Multiple Sclerosis: A Crossroads of Clues and Insights through Mast Cells, Platelets, Inflammation, Gut Microbiota, Mood Disorders and Stem Cells","volume":"23","author":"Cocchi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025121513015471000_15.6.e088808.28","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2011.205"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-088808","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:02:05Z","timestamp":1765832525000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-088808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/bmjopen-2024-088808"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-088808","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}